MedTrace Logo

Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis

NCT00510159 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2008-01-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of praziquantel versus As+SMP (Co-Arinate FDC ®) in the treatment of Schistosoma haematobium in 6-15 year old Malian children. The nul-hypothesis in this study is that the combination of As+SMP is more effective than praziquantel in the treatment of S. haematobium infected children.

Conditions

  • Schistosoma Haematobium

Interventions

DRUG

Artesunate+Sulfamethoxypyrazine/pyrimethamin

DRUG

Praziquantel

Sponsors & Collaborators

  • Dafra Pharma

    lead INDUSTRY

Principal Investigators

  • Mahamadou S Sissoko, MD, MSPH · University of Bamako, Mali

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2007-10-31
Completion
2007-12-31

Countries

  • Mali

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00510159 on ClinicalTrials.gov